Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
18.4M
-
Number of holders
-
20
-
Total 13F shares, excl. options
-
252K
-
Shares change
-
+29K
-
Total reported value, excl. options
-
$910K
-
Value change
-
+$57.1K
-
Number of buys
-
6
-
Number of sells
-
-1
-
Price
-
$3.61
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q1 2024
23 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q1 2024.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 20 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 252K shares
of 18.4M outstanding shares and own 1.37% of the company stock.
Largest 10 shareholders include Wellington Shields Capital Management, LLC (92.2K shares), Wellington Shields & Co., LLC (43.1K shares), HOWLAND CAPITAL MANAGEMENT LLC (40.4K shares), RENAISSANCE TECHNOLOGIES LLC (36.8K shares), GEODE CAPITAL MANAGEMENT, LLC (22.2K shares), WELLS FARGO & COMPANY/MN (12K shares), Catalyst Funds Management Pty Ltd (1.81K shares), MORGAN STANLEY (1.44K shares), SIMPLEX TRADING, LLC (623 shares), and FMR LLC (500 shares).
This table shows the top 20 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.